Consort Med Plc ADR (CSRMY) 13.4000 $CSRMY
The European Injectable Drug Delivery Technologies Expected to Reach $12.4 Billion by 2017 at a CAGR of 12.7% from 2012 To 2017
M2 - Wed Feb 26, 7:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/37kjcm/european) has announced the addition of the "European Injectable Drug Delivery - Market Forecasts to 2017" report to their offering. This research report categorizes the European injectable drug delivery technologies market into two segments, namely, Europe injectable drug delivery devices technologies and European injectable drug delivery formulations technologies. These markets are broken down into segments and sub-segments, providing value analysis for 2010, 2011, and 2012, as well as forecast up to 2017. Each market is comprehensively analyzed by geography (Germany, France, U.K., Spain, Italy, Russia and Rest of Europe (RoE)) to provide in-depth information on the European scenario. The European injectable drug delivery technologies market was valued at $6.8 billion in 2012, and is expected to reach $12.4 billion by 2017 at a CAGR of 12.7% from 2012 to 2017. Injectable drug delivery technologies are a combination of two major segments - devices and formulations. The European injectable drug delivery formulations technologies market is the largest segment in the market. This is due to a surge of biologics and the development of nanotechnologies. In addition, the market is segmented on the basis of its therapeutic applications. In the therapeutic field, hormonal disorders command the major segment due to the high demand of injectable in the treatment of diabetes. The growth of the injectable drug delivery technologies market is primarily triggered by favorable reimbursement policies on injectable drugs and devices, technological advancements, surge of biologics in pharmaceutical markets, rising incidences of cancer and diabetes in Europe, and improving patient compliance. The evolving opportunities in this market for manufacturers include development of biosimilars in pharmaceutical markets and focus of pharmaceutical manufacturers towards emerging markets such as Spain, Russia, Denmark, Ireland and others. However, factors such as needle-stick injuries and infections and development of alternate delivery methods are restraining the growth of the market. Companies Mentioned: - Alkermes, Inc - Bespak Europe, Ltd (Subsidiary Of Consort Medical, Plc) - Crossject - Gerresheimer AG - Haselmeier Gmbh - Injex Pharma Gmbh (Subsidiary Of Hns International, Inc) - Novo Nordisk A/S - Owen Mumford, Ltd - Sanofi - Schott AG - Vetter Pharma-Fertigung Gmbh & Co KG - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/37kjcm/european About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BMO: 70.35 (+0.15), NVO: 43.80 (+1.08), ALKS: 56.16 (+1.02)
The European Injectable Drug Delivery Technologies Expected to Reach $12.4 Billion by 2017 at a CAGR of 12.7% from 2012 To 2017
M2 - Wed Feb 26, 7:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/37kjcm/european) has announced the addition of the "European Injectable Drug Delivery - Market Forecasts to 2017" report to their offering. This research report categorizes the European injectable drug delivery technologies market into two segments, namely, Europe injectable drug delivery devices technologies and European injectable drug delivery formulations technologies. These markets are broken down into segments and sub-segments, providing value analysis for 2010, 2011, and 2012, as well as forecast up to 2017. Each market is comprehensively analyzed by geography (Germany, France, U.K., Spain, Italy, Russia and Rest of Europe (RoE)) to provide in-depth information on the European scenario. The European injectable drug delivery technologies market was valued at $6.8 billion in 2012, and is expected to reach $12.4 billion by 2017 at a CAGR of 12.7% from 2012 to 2017. Injectable drug delivery technologies are a combination of two major segments - devices and formulations. The European injectable drug delivery formulations technologies market is the largest segment in the market. This is due to a surge of biologics and the development of nanotechnologies. In addition, the market is segmented on the basis of its therapeutic applications. In the therapeutic field, hormonal disorders command the major segment due to the high demand of injectable in the treatment of diabetes. The growth of the injectable drug delivery technologies market is primarily triggered by favorable reimbursement policies on injectable drugs and devices, technological advancements, surge of biologics in pharmaceutical markets, rising incidences of cancer and diabetes in Europe, and improving patient compliance. The evolving opportunities in this market for manufacturers include development of biosimilars in pharmaceutical markets and focus of pharmaceutical manufacturers towards emerging markets such as Spain, Russia, Denmark, Ireland and others. However, factors such as needle-stick injuries and infections and development of alternate delivery methods are restraining the growth of the market. Companies Mentioned: - Alkermes, Inc - Bespak Europe, Ltd (Subsidiary Of Consort Medical, Plc) - Crossject - Gerresheimer AG - Haselmeier Gmbh - Injex Pharma Gmbh (Subsidiary Of Hns International, Inc) - Novo Nordisk A/S - Owen Mumford, Ltd - Sanofi - Schott AG - Vetter Pharma-Fertigung Gmbh & Co KG - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/37kjcm/european About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BMO: 70.35 (+0.15), NVO: 43.80 (+1.08), ALKS: 56.16 (+1.02)
